Toxoplasmosis: Difference between revisions

 
(10 intermediate revisions by 4 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Most common cause of focal encephalitis in patients with AIDS
*Most common cause of focal encephalitis in patients with AIDS
*Risk at CD4 < 100 and not on prophylaxis


==Clinical Features==
==Clinical Features==
#Headache
*[[Headache]]
#Fever
*[[Fever]]
#Focal neurologic deficits
*[[Focal neurologic deficits]]
#AMS
*[[altered mental status]]
#Seizures
*[[Seizures]]


==Diagnosis==
==Differential Diagnosis==
*Head CT w/o contrast
**Shows multiple subcortical lesions w/ predilection for basal ganglia
**Contrast usually not needed; if obtained, will show ring enhancing lesions
*CSF
**Helpful but high rate of false negatives
 
==DDX==
*Lymphoma
*Lymphoma
**More commonly single lesion in the periventricular white matter or corpus callosum
**More commonly single lesion in the periventricular white matter or corpus callosum
*Cerebral TB
*Cerebral TB
**Characteristic inflammatory appearance w/ isodense exudate filling basal cisterns
**Characteristic inflammatory appearance with isodense exudate filling basal cisterns
*Fungal infection
*[[Fungal infection]]
 
{{HIV associated conditions}}
 
==Evaluation==
*[[Head CT]] without contrast
**Shows multiple subcortical lesions with predilection for basal ganglia
**Contrast usually not needed; if obtained, will show ring enhancing lesions
*[[CSF]]
**Helpful but high rate of false negatives
*Serology not generally helpful since antibodies common in general population


==Treatment==
==Management==


===[[Antibiotics]]===
===[[Antibiotics]]===
Line 29: Line 33:


===Steroids===
===Steroids===
*Consider dexamethasone 4mg IV q6hr for significant edema or mass effect
*Consider [[dexamethasone]] 4mg IV q6hr for significant edema or mass effect


===Folinic Acid===
===Folinic Acid===
''Administer if the treatment regimen includes Leucovorin''
''Administer if the treatment regimen includes Leucovorin''
*Folinic acid 10mg PO QD x6–8wk
*[[Folinic acid]] 10mg PO QD x6–8wk


==Disposition==
==Disposition==
*Admit
*Admit


==Source==
==References==
<references/>
<references/>


[[Category:ID]]
[[Category:ID]]

Latest revision as of 09:28, 28 January 2018

Background

  • Most common cause of focal encephalitis in patients with AIDS
  • Risk at CD4 < 100 and not on prophylaxis

Clinical Features

Differential Diagnosis

  • Lymphoma
    • More commonly single lesion in the periventricular white matter or corpus callosum
  • Cerebral TB
    • Characteristic inflammatory appearance with isodense exudate filling basal cisterns
  • Fungal infection

HIV associated conditions

Evaluation

  • Head CT without contrast
    • Shows multiple subcortical lesions with predilection for basal ganglia
    • Contrast usually not needed; if obtained, will show ring enhancing lesions
  • CSF
    • Helpful but high rate of false negatives
  • Serology not generally helpful since antibodies common in general population

Management

Antibiotics

Immunocompetent

Antibiotics only needed if patient has severe symptoms

Immunosprepressed

Pregnant

  • Spiramycin 1 g orally every 8 hours[2]
    • If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses)
    • Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR
  • Pyrimethamine (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND
    • Leucovorin 10-25 mg/day orally to prevent bone marrow suppression

Steroids

  • Consider dexamethasone 4mg IV q6hr for significant edema or mass effect

Folinic Acid

Administer if the treatment regimen includes Leucovorin

Disposition

  • Admit

References

  1. Gutteridge, David L MD, MPH, Egan, Daniel J. MD. The HIV-Infected Adult Patient in The Emergency Department: The Changing Landscape of the Disease. Emergency Medicine Practice: An Evidence-Based Approach to Emergency Medicine. Vol 18, Num 2. Feb 2016.
  2. Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.